2.1
Leniolisib (Joenja, Pharming) is indicated for 'the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older'.
Open for comments Open until Request commenting lead permission
We have updated this service so that members of the same organisation can now collaborate on a joint online response.
Read our blog to learn more.
Leniolisib (Joenja, Pharming) is indicated for 'the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older'.
The dosage schedule is available in the summary of product characteristics for leniolisib.
The company has a commercial arrangement, which would have applied if the leniolisib had been recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation